London open: Housing, oil stocks help markets rebound from eight-week low
6th Dec 2013 08:52
- Housing and oil stocks provide a lift - Focus on Fed ahead of non-farm payrolls - Berkeley jumps as strong housing demand boosts H1 results techMARK 2,650.07 +0.07% FTSE 100 6,518.46 +0.31% FTSE 250 15,166.21 +0.06% The FTSE 100 rebounded slightly on Friday from an eight-week low, as bargain hu
Read moreLondon pre-open: Small rebound expected ahead of US jobs report
6th Dec 2013 07:37
Markets are expected to open slightly higher on Friday morning, rebounding after recent losses which have sent the FTSE 100 to an eight-week low, as investors look ahead to some key economic data out from the States this afternoon. City sources predict the FTSE 100 will open up around 13 points low
Read moreAstraZeneca receives European approval for child flu vaccine
6th Dec 2013 07:18
Pharmaceutical giant AstraZeneca has announced that the European Commission (EC) has granted marketing authorisation to its nasally administered four-strain flu vaccine Fluenz Tetra. The vaccine, aimed for the prevention of influenza in children and adolescents from 24 months to 18 years of age, i
Read moreLondon close: FTSE closes slightly lower after data-heavy week
22nd Nov 2013 16:48
- FTSE down seven points, 19 on the week - German GDP in-line - Former Co-op Bank Chairman arrested - TUI sinks on share sale - AstraZeneca rises on recommendation from EMA techMARK 2,642.04 +0.25% FTSE 100 6,674.30 -0.11% FTSE 250 15,187.68 +0.26% The final session of the week saw the FTSE end se
Read moreAstrazeneca rises on progress with diabetes drug
22nd Nov 2013 15:28
Shares in biopharmaceutical business AstraZeneca received a boost on Friday afternoon after the company, alongside sector peer Bristol-Myers Squibb, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended approval of Xigduo, a t
Read moreFTSE 100 movers: AstraZeneca rises on drug recommendation, TUI sinks
22nd Nov 2013 15:19
Shares in biopharmaceutical business AstraZeneca received a boost on Friday afternoon after the company, alongside sector peer Bristol-Myers Squibb, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended approval of Xigduo, a t
Read moreFTSE 100 movers: Johnson Matthey tops leaders after results impress
21st Nov 2013 15:07
Shares in speciality chemicals company Johnson Matthey leapt to the top of the leaderboard after it reported a robust set of half-year results, powered by a strong performance in Emission Control Technologies ahead of new European legislation and good demand for Process Technologies' products. The
Read moreWednesday broker round-up UPDATE
20th Nov 2013 08:46
Afren: Liberum Capital raises target price from 197p to 232p and maintains a buy recommendation. AstraZeneca: Berenberg cuts target price from 3472p to 3430p reiterating a hold recommendation. AVEVA Group: Liberum Capital reduces target price from 2350p to 2250p and keeps its hold recommendation.
Read moreFDA accepts AstraZeneca's new drug application
19th Nov 2013 07:37
AstraZeneca said the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for naloxegol, which is used for the treatment of opioid-induced constipation (OIC). The company filed the NDA after completing the Phase III KODIAC programme, which included four clinical trials
Read moreFriday broker round-up UPDATE
15th Nov 2013 07:38
Amlin: Berenberg raises target price from 398p to 434p, but still recommends selling. Barclays cuts target price from 481p to 453p and retains an overweight rating. Antofagasta: Numis raises target price from 750p to 850p and reiterates a hold recommendation. AstraZeneca: Liberum Capital upgrades
Read moreWednesday broker round-up
13th Nov 2013 12:33
AMEC: Credit Suisse downgrades from outperform to neutral with a target price of 1250p. Antofagasta: Alphavalue lowers target price from 1000.6p to 999.5p, while upgrading from add to buy. Associated British Foods: Credit Suisse raises target price from 1850p to 2250p and keeps a neutral rating.
Read moreMonday broker round-up UPDATE
4th Nov 2013 08:07
Aggreko: Cantor Fitzgerald reduces target price from 2200p to 1700p downgrading to hold. Anglo American: Alphavalue upgrades from add to buy with a target price of 1801.3p. APR Energy: Cantor Fitzgerald raises target price from 670p to 1000p, but still recommends selling. Astra Zeneca: UBS reduce
Read moreAdvanced Computer Software Chairman trades in 1m shares
1st Nov 2013 16:08
The Chairman of Advanced Computer Software this week sliced off 870,380 pounds-worth of shares from his stake, reducing it to 2.42m, the group announced after the close on Thursday. Michael Jackson disposed of exactly 1m shares in the healthcare and business management software, and said he made t
Read moreFTSE 100 movers: BT jumps after impressing with Sport package
31st Oct 2013 13:26
Telecomms heavyweight BT today reported a 13 per cent decline in half-year pre-tax profits to 948m pounds, but said the recently introduced BT Sport package had made a 'confident start'. Shares in the group floated higher, encouraged by a 13 per cent jump in the interim dividend to 3.4p and a reaffi
Read moreBroker snap: AstraZeneca a 'hold' after Q3 results, says Panmure
31st Oct 2013 11:43
AstraZeneca's shares fell on Thursday after it reported third quarter results that fell short of consensus, but broker Panmure Gordon recommended the shares be held. Revenues were down 4% to $6.2bn due to the impact from products with loss of patent protection on key drugs. It compared to the $6.38
Read more